KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Short-term Investments: 2020-2024

Historic Short-term Investments for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $3.0 million.

  • Recursion Pharmaceuticals' Short-term Investments rose 101.67% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 101.67%. This contributed to the annual value of $3.0 million for FY2024, which is 5.76% down from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Short-term Investments is $3.0 million, which was down 5.76% from $3.2 million recorded in FY2023.
  • Recursion Pharmaceuticals' Short-term Investments' 5-year high stood at $231.4 million during FY2021, with a 5-year trough of $1.3 million in FY2022.
  • Its 3-year average for Short-term Investments is $2.5 million, with a median of $3.0 million in 2024.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Short-term Investments spiked by 11,472.30% in 2021, and later crashed by 99.45% in 2022.
  • Recursion Pharmaceuticals' Short-term Investments (Yearly) stood at $2.0 million in 2020, then surged by 11,472.30% to $231.4 million in 2021, then crashed by 99.45% to $1.3 million in 2022, then spiked by 152.42% to $3.2 million in 2023, then fell by 5.76% to $3.0 million in 2024.